04 May 26
Building a biotech company from the ground up requires more than strong science. Early success depends on making a small number of critical decisions well, defining a clear direction for the company, choosing where to focus and building a development plan that balances scientific ambition with regulatory, clinical and commercial reality. For emerging teams, the strongest foundations are often laid long before a product reaches the clinic.
Vision, Focus and the Target Product Profile Set the Direction
At the earliest stage of development, companies need clarity on what success looks like and how they plan to get there. That starts with defining a shared vision, choosing a clear strategic focus and developing a target product profile that acts as a blueprint for the programme. Without these foundations, it becomes much harder to align decisions, prioritise resources and build a product that can succeed in a competitive market.
Define what success looks like. A clear vision helps teams align around a common destination and shared objectives.
Choose strategic focus carefully. Small companies have limited resources, so market analysis, unmet need and disciplined prioritisation are essential.
Build around a target product profile. A strong TPP helps shape development decisions early and keeps the programme focused on a product that will be competitive at launch.
Early Planning Reduces Risk Later
The transcript makes clear that early development decisions have long-term consequences. From candidate selection onward, companies need to understand what data will be required, which milestones matter and what trade-offs may shape progress. Teams that seek information early are better placed to avoid costly backtracking later.
Keep options open, but stay focused. Drug development always carries risk, so it is sensible to have a backup strategy without trying to pursue too many directions at once.
Map the pathway early. Understanding the route from preclinical work through IND and clinical development helps align timelines, expectations and investment needs.
Do not wait to ask questions. The real risk is rarely asking too early, but asking too late and losing time, money and momentum.
Regulatory and Commercial Thinking Must Start Early
Strong programmes do not separate science from commercial or regulatory strategy. Developers need early regulatory input to understand what evidence will be required, while commercial analysis helps clarify unmet need, market opportunity and investor relevance. Together, these perspectives help ensure that development is focused not just on scientific progress, but on creating a viable product.
Engage regulators early. Early dialogue helps companies understand requirements during candidate selection and preclinical planning, and can reduce downstream risk.
Build the business case early. Investors need to see clear thinking on market need, value proposition, delivery strategy, team capability and return on investment.
Align milestones with reality. Companies need to understand the data, timing, cost and inflection points that define a realistic path to market.
The Right Expertise and Partnerships Matter
Most early biotech companies cannot hold every capability in-house, especially at the start. That makes external expertise, advisory input and carefully chosen partnerships especially important. The key is to identify capability gaps early and fill them in a way that supports continuity, decision-making and progress.
Know where support is needed. Regulatory, preclinical, CMC, formulation and commercial expertise may all need to be brought in early.
Use flexible models intelligently. Fractional support, consultants and advisory boards can help startups access critical expertise without overbuilding headcount.
Build relationships that last. In areas such as regulatory and clinical development, long-term external partnerships can provide continuity and stronger strategic support.
Team Alignment is a Competitive Advantage
The transcript also highlights that progress depends on aligning very different stakeholders around shared goals. Academic founders, investors, operational teams and commercial leaders often work to different timeframes and priorities. The companies that move forward most effectively are those that create a team culture with clear ownership, realistic milestones and collective commitment to delivery.
Bridge different mindsets. Academic, operational and commercial teams may approach development differently, so alignment is essential.
Manage investor expectations carefully. Milestones need to be ambitious but achievable, with a realistic view of timelines and development risk.
Work as one team. Shared objectives and joint accountability help keep programmes moving in the right direction.
Key Insight
The strongest biotech foundations are built early. By defining success clearly, focusing on the right opportunity, engaging regulators and commercial thinking from the outset and filling capability gaps with the right expertise, emerging companies can create a more credible, resilient and development-ready path forward.
Contact Us
tranScrip supports biotech innovators with the strategic, regulatory, clinical and commercial expertise needed to move from early concept to confident development. Whether you are shaping your first programme or refining your route to clinic, our experts can help you build the right foundations.
Hear more in Episode 1 of tranScrip Talks, where Rienk Pypstra is joined by David Findley, CEO of Rostra Therapeutics, to discuss the decisions that shape successful biotech development from the very beginning.
Get in touch to see how our senior cross-functional experts can help you reduce risk, protect value, and move forward with confidence.